With only seven genes, the BK polyomavirus must use the host cell's DNA replication machinery to produce new viruses. Although the virus was discovered over 50 years ago, little is known about how ...
Orthogon Therapeutics, a developer of novel antiviral medicines, today announced the closing of an oversubscribed financing round, exceeding its $5M target and bringing total funding to over $25M.
orally available drug for treating polyomavirus infections. The compound is in pre-investigational new drug (IND) development for BK virus infections in transplant patients. A second group of ...